Weekly Investment Analysts’ Ratings Changes for BlossomHill Therapeutics (BLSM)

BlossomHill Therapeutics (NASDAQ: BLSM) has recently received a number of price target changes and ratings updates:

• 9/1/2026 – BlossomHill Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $36.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $30.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $35.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by Lifesci Capital. They set an “outperform” rating and a $32.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $28.00 price target on the stock.
• 8/15/2026 – BlossomHill Therapeutics was upgraded by Wall Street Zen to “hold”.

Insiders Place Their Bets

In other BlossomHill Therapeutics news, Director John P. Schmid bought 6,000 shares of BlossomHill Therapeutics stock in a transaction on Monday, August 10th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $96,000.00. Following the completion of the acquisition, the director owned 6,000 shares in the company, valued at approximately $96,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Vincent Paul Liptak bought 2,200 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, with a total value of $35,200.00. Following the completion of the purchase, the general counsel owned 111,412 shares of the company’s stock, valued at approximately $1,782,592. This trade represents a 2.01% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 1,573,900 shares of company stock worth $25,181,900 over the last 90 days.

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.